论文部分内容阅读
目的观察注射用重组人干扰素α-1b压缩雾化吸入治疗小儿病毒性下呼吸道感染的临床效果。方法选取2015年2月-2016年3月于该院就诊的小儿下呼吸道感染患儿98例,通过动态随机化法分为观察组和对照组各49例,对照组采用常规方法治疗,观察组采用常规方法联合注射用重组人干扰素α-1b压缩雾化吸入治疗,观察2组患儿咳嗽消失时间、体温正常时间及治疗效果。结果观察组患儿的咳嗽消失时间及体温正常时间均短于对照组,总有效率高于对照组,差异均有统计学意义(P<0.05)。结论注射用重组人干扰素α-1b雾化吸入治疗小儿病毒性下呼吸道感染能有效缓解患儿的临床症状,从而改善治疗效果,临床可推广应用。
Objective To observe the clinical effect of injecting recombinant human interferon α-1b compressed atomized inhalation in treating pediatric viral lower respiratory tract infection. Methods A total of 98 pediatric children with lower respiratory tract infection were selected from February 2015 to March 2016 in our hospital. The patients were divided into observation group and control group by dynamic randomization method. The control group was treated by conventional method. The observation group The conventional method combined with injection of recombinant human interferon α-1b compression atomization inhalation therapy, two groups of children with cough disappear time, body temperature normal time and treatment effect. Results The disappearance time of cough and normal body temperature in observation group were shorter than those in control group, and the total effective rate was higher than that in control group (P <0.05). Conclusion Injecting recombinant human interferon α-1b aerosol inhalation for the treatment of pediatric viral lower respiratory tract infection can effectively relieve the clinical symptoms of children, thereby improving the therapeutic effect, which can be popularized clinically.